Petros Pharmaceuticals, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Petros Pharmaceuticals, Inc. (PTPI) reported Increase (Decrease) in Other Noncurrent Liabilities of -$62.43 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-12-31 was -$16.61K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-09-30 was -$15.92K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-06-30 was -$15.27K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-03-31 was -$14.64K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$62.43K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$125.02K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was -$142.34K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2021 was -$195.90K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$16.61K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$32.53K derived: sum of 2 quarters · filed 2025-03-31 | -$47.80K derived: sum of 3 quarters · filed 2025-03-31 | -$62.43K 10-K · filed 2025-03-31 |
| 2024-09-30 | -$15.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$31.19K derived: sum of 2 quarters · filed 2024-11-13 | -$45.83K 10-Q · filed 2024-11-13 | -$59.56K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$15.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$29.90K 10-Q · filed 2024-08-14 | -$43.64K derived: sum of 3 quarters · filed 2025-03-31 | -$75.57K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$14.64K 10-Q · filed 2024-05-15 | -$28.37K derived: sum of 2 quarters · filed 2025-03-31 | -$60.31K derived: sum of 3 quarters · filed 2025-03-31 | -$100.55K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$13.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$45.67K derived: sum of 2 quarters · filed 2025-03-31 | -$85.92K derived: sum of 3 quarters · filed 2025-03-31 | -$125.02K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$31.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$72.18K derived: sum of 2 quarters · filed 2024-11-13 | -$111.28K 10-Q · filed 2024-11-13 | -$148.76K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$40.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$79.35K 10-Q · filed 2024-08-14 | -$116.82K derived: sum of 3 quarters · filed 2024-08-14 | -$152.78K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$39.10K 10-Q · filed 2024-05-15 | -$76.58K derived: sum of 2 quarters · filed 2024-05-15 | -$112.53K derived: sum of 3 quarters · filed 2024-05-15 | -$147.48K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$37.48K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$73.43K derived: sum of 2 quarters · filed 2024-04-01 | -$108.38K derived: sum of 3 quarters · filed 2024-04-01 | -$142.34K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$35.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | -$70.90K derived: sum of 2 quarters · filed 2023-11-15 | -$104.86K 10-Q · filed 2023-11-15 | -$137.60K derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | -$34.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$68.91K 10-Q · filed 2023-08-14 | -$101.64K derived: sum of 3 quarters · filed 2023-08-14 | -$133.46K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$33.97K 10-Q · filed 2023-05-15 | -$66.70K derived: sum of 2 quarters · filed 2023-05-15 | -$98.52K derived: sum of 3 quarters · filed 2023-05-15 | -$129.46K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$32.73K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | -$64.56K derived: sum of 2 quarters · filed 2023-03-31 | -$95.49K derived: sum of 3 quarters · filed 2023-03-31 | -$195.90K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$31.82K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | -$62.76K derived: sum of 2 quarters · filed 2022-11-15 | -$163.17K 10-Q/A · filed 2022-11-15 | -$193.40K derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | -$30.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$131.35K 10-Q · filed 2022-08-12 | -$161.57K derived: sum of 3 quarters · filed 2022-08-12 | -$204.22K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$100.41K 10-Q · filed 2022-05-16 | -$130.63K derived: sum of 2 quarters · filed 2022-05-16 | -$173.28K derived: sum of 3 quarters · filed 2022-05-16 | -$224.03K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$30.23K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$72.87K derived: sum of 2 quarters · filed 2022-03-31 | -$123.62K derived: sum of 3 quarters · filed 2022-03-31 | -$148.63K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$42.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$93.39K derived: sum of 2 quarters · filed 2021-11-15 | -$118.40K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$50.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$75.75K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$25.01K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |